AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)| Amgen

Amgen (AMGN) reported positive results from a Phase 3B study of Repatha (evolocumab) in HIV+ patients with high LDL-C. The study showed significant LDL-C reduction, meeting its primary endpoint. Results were presented at ACC.20/WCC and published in JACC.

Amgen reported positive Phase 3 trial results for Otezla in mild-to-moderate plaque psoriasis. The study met primary and secondary endpoints, showing significant improvement compared to placebo. Amgen plans to discuss these results with the FDA. Otezla is already approved for moderate-to-severe plaque psoriasis and other indications. The trial involved 595 patients.

Amgen (AMGN) and Cytokinetics (CYTK) announced FDA Fast Track designation for omecamtiv mecarbil, a potential treatment for chronic heart failure with reduced ejection fraction. The designation may expedite the drug's review process. Top-line results from the GALACTIC-HF Phase 3 trial are expected in Q4 2020.

Amgen invested $421M in BeiGene's share offering, maintaining a 20.3% stake. The investment supports their oncology collaboration in China, reflecting confidence in the partnership's progress.

Amgen (AMGN) launched exchange offers for nine series of its senior notes, proposing to issue new notes and cash payments totaling up to $800M. The offers, open until August 26, prioritize early participants and certain note series.

Amgen announced a U.S. appeals court upheld two Enbrel patents, affirming a 2019 ruling against Sandoz's biosimilar. The injunction prohibits Sandoz from selling its etanercept product. Amgen affiliates and Roche hold the patents.